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Abstract
Background: Desmoid tumors are a group of benign, invasive, solid tumors that are relatively rare in the general
population, but can occur in up to 21 % of patients with Familial Adenomatous Polyposis (FAP). They can be
difficult to treat and have high rates of recurrence even after resection. Our goal with this study was to identify
the genetic mutations that put certain patients with FAP at high risk for desmoid tumors and could be future
targets for research.
Methods: We performed a search in Pubmed, Ovid Medline and Embase to identify subjects with desmoid
tumors and FAP. As a reference group for APC mutations in the unselected FAP population, we used the UMD-APC
database referenced in the Orphanet portal which includes APC mutation data on 2040 individuals with FAP.
Results: Mutations were able to be broken down into 7 regions based on previously published data. Mutations in the
APC gene from codons 1310 to 2011 were the most common region encompassing 48 % of published desmoid cases
and 40 % of the reference population. It had a slightly elevated odds ratio of 1.4 that was statistically significant along
with codon region 543-713 that had an odds ratio of 2.0. Using a combination of p-value and CI, the remaining 5
regions did not meet statistical significance as either the p >0.05 or the CI included 1.0. The most common point
mutation found was codon 1309 (13.1 %), but it was also the most commonly found mutation in our reference
population (12.9 %) and had an odds ratio of 1.0.
Conclusions: There is an increased risk for desmoid tumors in individuals with APC mutations between codons
543-713 and 1310-2011 when compared to a reference population. These patients may benefit from further study
to develop surveillance protocols that could improve outcomes.
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Background
Familial Adenomatous Polyposis (FAP) is an autosomal
dominant syndrome characterized by profuse adenomatous
polyposis in the colon and rectum with nearly 100 % life-
time risk of colorectal cancer [1]. Germline mutations with
frameshift or nonsense codes in the adenomatous polyposis
coli (APC) gene on chromosome 5q21 cause the majority
of cases of FAP [2]. More than 60 % of APC mutations
are found in the mutation cluster region(MCR) between
codons 1284 and 1580 [3], or 1284–1464 [4]. The two
most frequently described germline mutations are located
at codon 1309 (c3927_3931delAAAGA) and codon 1061
(c.3183_87delACAAA) [5].
Penetrance is variable for extra-colonic manifestations,
but contributes significantly to the morbidity and mortality
of patients post-colectomy. Disease expression in FAP is to
some extent dependent on the specific APC mutations and
all patients identified with FAP need to be assessed regu-
larly from birth. Extra-colonic manifestations in children
with FAP may include an increased risk of hepatoblastoma
[6, 7], medulloblastoma [8], osteomas, supernumerary teeth
or missing teeth, congenital hypertrophy of retinal pigment
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epithelium (CHRPE), desmoid tumors, thyroid cancers, and
fibromas. Several referral centers have adopted an extra-
intestinal tumor surveillance strategy that includes reported
genotype-phenotype correlations [9, 10].
Desmoid tumors are a significant concern in patients
post-colectomy and cause significant morbidity and mortal-
ity [11]. The overall lifetime risk in some patient registries
of FAP for desmoids tumors is as high as 21 % [12, 13]. Risk
factors include prior surgery, positive family history, os-
teomas, and epidermoid cysts [12]. Despite their common
occurrence in FAP, they are poorly understood, histologi-
cally benign lesions. They are not associated with distant
metastases, but can cause significant morbidity from local
tissue compression from growth. Symptoms generally
depend on the location of the tumor and can range from
asymptomatic to aesthetic changes, pain, bowel obstruc-
tion, musculoskeletal dysfunction, abscess formation, and
vascular compression.
Previously, it was felt that the risk for desmoids tumors
was most severe in patients with FAP whose mutations
were between codons 1444 and 1578 [12]. However, this
was based on observations on detected mutations in affected
patients without comparison to a reference population.
This study is a systematic review of the genotype-
phenotype associations of desmoids tumors in patients
with FAP (Additional file 1). A literature search was
undertaken to find all cases of desmoids tumors that
had a described mutation in the APC gene. This was
further refined by controlling for the frequency distri-
bution of mutations in a reference database of APC
gene mutations in FAP patients. The aim of this study
is to better define the correlation between APC gene
mutations and desmoid tumor formation. This could
provide future targets of research for pathophysiology
and surveillance programs.
Methods
All authors performed a search in Pubmed, Ovid Medline
and Embase with the two terms:
 ((“Adenomatous Polyposis Coli”[Mesh] OR “Genes,
APC”[Mesh] OR “Adenomatous Polyposis Coli
Protein”[Mesh]) AND “Genetic Phenomena”[mesh])
AND “Epidemiologic Studies”[Mesh] AND
(“Fibroma”[Mesh] OR desmoid) AND English[lang].
 (“Fibroma”[Mesh] OR desmoid) AND ((kindred* OR
family OR “Family”[Mesh] OR “Pedigree”[Mesh])
AND (“Adenomatous Polyposis Coli”[Mesh] OR
“Genes, APC”[Mesh] OR “Adenomatous Polyposis
Coli Protein”[Mesh]) AND “Genetic
Phenomena”[mesh] AND English[lang]
Our search results were reviewed by all authors. Articles
in the reference lists of the retrieved articles were also
reviewed to identify additional studies. All of the authors
collectively abstracted information from each of these
studies. Each published case was reviewed for data points
including sample size, diagnosis of FAP, diagnosis of
desmoids tumor, and documentation of APC mutation.
Studies with duplicate patient reports were excluded. The
remaining patients were accrued into a database where
information relating to gender, age of onset for desmoid
tumors, desmoid tumor location, and specific mutations
of APC gene were collected for further evaluation. As a
reference group for APC mutations in the unselected FAP
population, we used the UMD-APC database referenced
in the Orphanet portal (http://www.umd.be/APC/). This
includes data on 2040 individuals with FAP including their
APC gene mutation.
When reviewing the published literature on desmoid
tumors, we found that many studies did not report spe-
cific point mutations of the APC gene. Instead, several
studies grouped patients together into ranges of codon
mutations. These ranges were often based on the results
of protein truncation tests commonly used to identify mu-
tations in the APC gene prior to sequencing. The largest
of the ranges was from a study by Bertario et al and this
was used as the basis for our statistical analysis [4]. Given
the rarity of both desmoid tumors and FAP, the decision
was made to include these patients into the database in
order to have as many published cases as possible. While
this would limit our ability to analyze specific codon mu-
tations, we are able to increase the statistical significance
for the codon mutation ranges. One codon was able to be
fully analyzed as a point mutation, 1309, and the results of
that analysis are included below.
Fisher’s exact test was performed to compare the muta-
tion rate between reference population and patients with
FAP and desmoids tumors. Odds ratio and 95 % exact
confidence interval were determined. The 95 % confidence
interval of significant odds ratio does not cross 1. Statis-
tical significance was claimed with p < 0.05. All statistical
analyses were performed in SAS 9.2 (Cary NC).
Results
The initial searches resulted in 51 unique articles related
to desmoids and FAP. After review, twenty six studies were
determined as meeting inclusion criteria. These twenty six
studies included a total of 274 reported cases of desmoids
tumors in patients with FAP. APC gene mutation testing
was reported in 222 patients [Table 1]. Of those 222 cases,
individuals were mainly female (63 F: 43 M) with an aver-
age age of 30.3 (+/− 27.0) years. The reference population
of individuals with FAP included 2040 individuals. We
compared the prevalence of APC mutations in the pub-
lished patients with desmoid tumors to the prevalence of
the same mutation in the reference population [Table 1].
The single most common location for a desmoid tumor
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was intra-abdominal; however, in total there were more
extra-abdominal tumors with the next two most common
locations being the abdominal wall itself and the extrem-
ities [Fig. 1].
When comparing our desmoid tumor database to pre-
viously published APC gene mutations, our database
was able to be broken down into 7 regions of the APC
gene. This was based on previously published data that
grouped APC mutations into smaller groups by location,
based in turn, on the method of testing for APC muta-
tion [4]. The odds ratios were between 0.9-2.0 [Table 1].
Mutations in the APC gene from codon 1310 to 2011
were the most common region encompassing 48 % of
published desmoids cases and 40 % of our reference
population [Fig. 2]. This region additionally had a slightly
elevated odds ratio of 1.4 (1.1 – 1.9) that was statistically
significant (p = 0.01). This region includes the codon re-
gion of 1444 and 1578 which has been previously sus-
pected to have increased risk of desmoid tumors [16].
However, when comparing published desmoid cases to the
reference population, we observed that another codon re-
gion, 543-713, had an even higher odds ratio for desmoid
tumors of 2.0 (1.2 – 3.3) that was also statistically signifi-
cant (p = 0.01). None of the remaining 5 codon regions
had statistically significant odds ratios. The most common
point mutation found in our affected patients was codon
1309 (13.1 %), but it was also the most commonly found
mutation in our reference population (12.9 %). The odds
ratio was 1.0 (0.6 – 1.5) which suggested no increased risk
when compared to our reference population. There was
an addition codon mutation region with an odds ratio of
2.0 (1.0 – 3.8) at codons 1256-1303 that was statistically
significant (p = 0.03). However, as the confidence interval
included 1.0 it could not be reliably confirmed as being at
higher risk for desmoid tumor formation.
Discussion
We believe that this is the largest group of pooled cases
that includes desmoid tumors and APC gene mutations
reported to date. The mean age of onset (30.0 years) tallies
with previously reported data. There was also a female pre-
dominance for desmoid tumors which has been reported in
thyroid carcinoma in FAP as well [14]. However, this is the
first analysis that attempts to define the actual risk of des-
moid tumors based on specific APC gene mutations while
adjusting for the frequency distribution of APC mutations
in an FAP reference population, in an attempt to obviate
bias toward more common mutations. Our group had pre-
viously performed a similar study regarding thyroid cancer
and FAP [14]. The observations from that study also re-
vealed the need to re-examine other recommendations on
phenotype-genotype correlations that are of even greater
clinical relevance such as desmoid tumors.
Previous authors have noted that desmoids were most
strongly associated with APC gene mutations from co-
dons 1309-1580. Our data does indicate that mutations
in codons 1310-2011 are associated with an increased
risk of desmoid tumors; however, codon 1309 itself does
not seem to confer an increased risk of desmoid tumor
alone. Individuals harboring mutation at codon 1309 may
be reported as associated with more extra-intestinal mani-
festations by virtue of being one of the more prevalent
mutations, but does not appear to be associated with an
increased risk of desmoid tumor formation when using
Table 1 Codon regions and their respective odds ratios for risk of desmoids tumors








Odds Ratio (CI) P-value
159-495 23 10 % 197 10 % 1.1 (0.7-1.7) 0.72
543-713 21 9 % 102 5 % 2.0 (1.2-3.3) 0.01
721-972 19 9 % 105 5 % 1.7 (1.0-2.9) 0.04
976-1067 19 9 % 184 9 % 0.9 (0.5-1.6) 0.9
1068-1237 19 9 % 150 7 % 1.2 (0.7-2.0) 0.5
1256-1303 14 6 % 65 3 % 2.0 (1.0-3.8) 0.03
1310-2011 107 48 % 810 40 % 1.4 (1.1-1.9) 0.01
Fig. 1 Pie chart showing published locations of desmoids tumors
associated with FAP (n = 195). The exact location of extra-abdominal
tumors are included in the figure when reported, but they were
often simply reported as “extra-abdominal”
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our methods. We made a similar observation in our earlier
work exploring the genotypic associations between FAP
and thyroid cancer [14]. This argues that higher risk co-
dons lay further down the 3′ end of this coding region.
Lastly, by comparing published data to a reference popula-
tion, we identified an even higher risk region within
543-713 that was not previously recognized for desmoid
tumors.
Genotype-directed disease surveillance has repeatedly
been proposed as a potential strategy geared toward the
detection of early intestinal and extra-colonic malignancy
in FAP. Whether the specific APC mutation prompts dif-
ferent desmoid tumor surveillance techniques and sched-
ules in certain groups of patients has not been previously
determined. A recent review of extra-abdominal desmoid
tumors did not reveal any specific surveillance guidelines
much less one based on genotype [15]. These results could
be used in future research to better understand the patho-
physiology of desmoid tumor formation or to develop
surveillance protocols for targeted codon mutations of
the APC gene.
This study has several limitations; it is a pooled meta-
analysis of a heterogeneous group of publications ran-
ging from registry based reports, case series, and case
reports. Although efforts were made to exclude duplicate
studies through careful scrutiny of publications from
the same author, group, or center we cannot be sure that
individual patients were not included in more than one
registry or seen at more than one center resulting in over-
representation in the final dataset. This appears to have
been unlikely given that duplicate identical clinical data
could not be found in the final dataset. The study also ne-
cessarily suffers from the inclusion of studies over a period
of time during which testing modalities for APC muta-
tions has changed. For example, some studies based their
results on protein truncation tests which provided a range
of mutations, but did not reveal specific point mutations.
Other studies based their results on sequencing which
revealed specific codon mutations. This resulted in an
accrual of data that can be challenging to compare. It is
noteworthy that our search revealed only 274 published
patients with FAP, a specified APC gene mutation, and
desmoid tumors. This underscores the need for a common
resource for the pooling of mutation analysis and clinical
features of this and other relatively rare polyposis syn-
dromes through expanded use of registries.
Conclusion
Our study reiterates the importance of continued clinical
vigilance for desmoid tumor disease. Building upon earlier
studies; however, we emphasize the increased risk in indi-
viduals with mutations at both the 5′ (543-713) and 3′
(1310-2011) regions of the APC gene. It is suggested that
these patients might benefit from future research to de-
velop targeted surveillance programs in an effort to reduce
morbidity and mortality from desmoids tumors in the set-
ting of FAP.
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Fig. 2 Bar graph comparing frequency of codon mutations in both the published cases of desmoid tumors and the reference population of FAP
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